Ibrutinib (Imbruvica) Market: Navigating the Patent Cliff And Coping With Generic Competition
- Published: Oct, 2025
- Report ID: GVR-MT-100442
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 120
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Ibrutinib (Imbruvica) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Ibrutinib (Imbruvica) Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.4. Chronic Lymphocytic Leukemia (CLL)
4.4.1. Chronic Lymphocytic Leukemia (CLL), 2021 - 2033 (USD Million)
4.5. Mantle Cell Lymphoma (MCL)
4.5.1. Mantle Cell Lymphoma (MCL) Market, 2021 - 2033 (USD Million)
4.6. Waldenström’s Macroglobulinemia (WM)
4.6.1. Waldenström’s Macroglobulinemia (WM) Market, 2021 - 2033 (USD Million)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Ibrutinib (Imbruvica) Market: End User Business Analysis
5.1. End User Market Share, 2024 & 2033
5.2. End User Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
5.4. Hospitals & Oncology Centers
5.4.1. Hospitals & Oncology Centers Market, 2021 - 2033 (USD Million)
5.5. Specialty Clinics / Hematology Centers
5.5.1. Specialty Clinics / Hematology Centers Market, 2021 - 2033 (USD Million)
5.6. Specialty Clinics / Hematology Centers
5.6.1. Others, 2021 - 2033 (USD Million)
5.6.2. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Ibrutinib (Imbruvica) Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.5. Europe
6.6. Asia Pacific
6.7. Latin America
6.8. Middle East and Africa
Chapter 7. Competitive Landscape
7.1. Company Profile
7.1.1. AbbVie Inc.
7.1.1.1. Overview
7.1.1.2. Financial Performance
7.1.1.3. Strategic Mapping
7.2. Biosimilar Producers
7.2.1. Amgen Inc.
7.2.1.1. Overview
7.2.1.2. Financial Performance
7.2.1.3. Product Benchmarking
7.2.1.4. Strategic Mapping
7.2.2. Mylan Pharmaceuticals (now part of Viatris)
7.2.2.1. Overview
7.2.2.2. Financial Performance
7.2.2.3. Product Benchmarking
7.2.2.4. Strategic Mapping
7.2.3. Biocon Biologics
7.2.3.1. Overview
7.2.3.2. Financial Performance
7.2.3.3. Product Benchmarking
7.2.3.4. Strategic Mapping
7.2.4. Hetero Drugs Ltd
7.2.4.1. Overview
7.2.4.2. Financial Performance
7.2.4.3. Product Benchmarking
7.2.4.4. Strategic Mapping
7.2.5. Dr. Reddy’s Laboratories
7.2.5.1. Overview
7.2.5.2. Financial Performance
7.2.5.3. Product Benchmarking
7.2.5.4. Strategic Mapping
7.3. Concurrent Competitors (Alternative Therapeutics)
7.3.1. AstraZeneca
7.3.1.1. Overview
7.3.1.2. Financial Performance
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Mapping
7.3.2. AstraZeneca
7.3.2.1. Overview
7.3.2.2. Financial Performance
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Mapping
7.3.3. Johnson & Johnson
7.3.3.1. Overview
7.3.3.2. Financial Performance
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Mapping
7.3.4. Sun Pharmaceutical Industries
7.3.4.1. Overview
7.3.4.2. Financial Performance
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Ibrutinib (Imbruvica) market, by region, 2021 - 2033 (USD Million)
Table 4 North America Ibrutinib (Imbruvica) market, by Indication, 2021 - 2033 (USD Million)
Table 5 North America Ibrutinib (Imbruvica) market, by End User, 2021 - 2033 (USD Million)
Table 6 Europe Ibrutinib (Imbruvica) market, by Indication, 2021 - 2033 (USD Million)
Table 7 Europe Ibrutinib (Imbruvica) market, by End User, 2021 - 2033 (USD Million)
Table 8 Asia Pacific Ibrutinib (Imbruvica) market, by Indication, 2021 - 2033 (USD Million)
Table 9 Asia Pacific Ibrutinib (Imbruvica) market, by End User, 2021 - 2033 (USD Million)
Table 10 Latin America Ibrutinib (Imbruvica) market, by Indication, 2021 - 2033 (USD Million)
Table 11 Latin America Ibrutinib (Imbruvica) market, by End User, 2021 - 2033 (USD Million)
Table 12 Middle East & Africa Ibrutinib (Imbruvica) market, by Indication, 2021 - 2033 (USD Million)
Table 13 Middle East Ibrutinib (Imbruvica) market, by End User, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Ibrutinib (Imbruvica) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market End User & validation
Fig. 8 Market snapshot
Fig. 9 Product outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Ibrutinib (Imbruvica) market dynamics
Fig. 12 Ibrutinib (Imbruvica) market: Porter’s five forces analysis
Fig. 13 Ibrutinib (Imbruvica) market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Chronic Lymphocytic Leukemia (CLL), 2021 - 2033 (USD Million)
Fig. 16 Mantle Cell Lymphoma (MCL) market, 2021 - 2033 (USD Million)
Fig. 17 Others market, 2021 - 2033 (USD Million)
Fig. 18 End User market, 2021 - 2033 (USD Million)
Fig. 19 Hospitals & Oncology Centers market, 2021 - 2033 (USD Million)
Fig. 20 Specialty Clinics / Hematology Centers market, 2021 - 2033 (USD Million)
Fig. 21 Others market, 2021 - 2033 (USD Million)
Fig. 22 Ibrutinib (Imbruvica) market revenue, by region
Fig. 23 Regional marketplace: Key takeaways
Fig. 24 North America Ibrutinib (Imbruvica) market, 2021 - 2033 (USD Million)
Fig. 25 Europe Ibrutinib (Imbruvica) market, 2021 - 2033 (USD Million)
Fig. 26 Asia Pacific Ibrutinib (Imbruvica) market, 2021 - 2033 (USD Million)
Fig. 27 Latin America Ibrutinib (Imbruvica) market, 2021 - 2033 (USD Million)
Fig. 28 MEA Ibrutinib (Imbruvica) market, 2021 - 2033 (USD Million)
Fig. 29 Company categorization
Fig. 30 Company market position analysis
Fig. 31 Strategic framework
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.